# US 2017/0290821 A1 · Anti-influenza virus agent and screening method for anti-influenza virus agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0290821 A1
- Document ID: US20170290821A1
- Status: Published application
- Kind: A1
- Application number: 15/511,930
- Filed: 2015-09-18
- Published: 2017-10-12
- Earliest claimed: 2014-09-22
- Assignees: Japan Science and Technology Agency
- Applicants: Japan Science and Technology Agency
- Inventors: Yoshihiro KAWAOKA; Tokiko WATANABE; Eiryo KAWAKAMI; Shinji WATANABE
- Web page: https://patentgrep.com/patent/US20170290821A1

## CPC

- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/47: from mammals
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 15/09: Recombinant DNA-technology
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Q 1/485: {involving kinase}
- C12Q 1/68: involving nucleic acids
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Y 207/10002: Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/5023: {on expression patterns}
- C07K 2319/43: containing a FLAG-tag
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2760/16111: Influenzavirus A, i.e. influenza A virus
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2500/10: involving cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides an anti-influenza virus agent that targets biomolecules of host cells including human cells and a method of screening a candidate molecule for the anti-influenza virus agent. That is, the present invention is an anti-influenza virus agent that has an effect of suppressing expression or a function of a gene that encodes a protein having an effect of suppressing incorporation of an influenza virus vRNA or an NP protein into influenza virus-like particles in host cells and the gene is at least one selected from the group including JAK1 gene and the like.

## Claims

### Claim 1

An anti-influenza virus agent that has an effect of suppressing expression of a gene that encodes a protein involved in incorporation of an influenza virus vRNA or an NP protein into influenza virus-like particles in host cells or an effect of suppressing a function of the protein,
wherein the gene is at least one selected from the group including JAK1 gene, CHERP gene, DDX21 gene, DNAJC11 gene, EEF1A2 gene, HNRNPK gene, ITM2B gene, MRCL3 gene, MYH10 gene, NDUFS8 gene, PSMD13 gene, RPL26 gene, SDF2L1 gene, SDF4 gene, SFRS2B gene, SNRPC gene, SQSTM1 gene, TAF15 gene, TOMM40 gene, TRM2B gene, USP9X gene, BASP1 gene, THOC2 gene, PPP6C gene, TESC gene, and PCDHB12 gene.

### Claim 2 (depends on 1)

The anti-influenza virus agent according to claim 1,
wherein the gene is JAK1 gene or USP9X gene.

### Claim 3 (depends on 1)

The anti-influenza virus agent according to claim 1,
wherein the anti-influenza virus agent is at least one selected from the group including Ruxolitinib, Tofacitinib, Tofacitinib (CP-690550) Citrate, Tyrphostin B42 (AG-490), Baricitinib (LY3009104, INCB028050), AT9283, Momelotinib, CEP33779, NVP-BSK805, ZM39923, Filgotinib, JANEX-1, NVP-BSK805, SB1317, and WPI 130.

### Claim 4

An anti-influenza virus agent having an effect of suppressing expression of a gene that encodes a protein involved in influenza virus replication or transcription in host cells or an effect of suppressing a function of the protein,
wherein the gene is at least one selected from the group including CCDC56 gene, CLTC gene, CYC1 gene, NIBP gene, ZC3H15 gene, C14orf173 gene, ANP32B gene, BAG3 gene, BRD8 gene, CCDC135 gene, DDX55 gene, DPM3 gene, EEF2 gene, IGF2BP2 gene, KRT14 gene, and S100A4 gene.

### Claim 5

An anti-influenza virus agent having an effect of suppressing expression of a gene that encodes a protein involved in formation of influenza virus-like particles in host cells or an effect of suppressing a function of the protein,
wherein the gene is at least one selected from the group including GBF1 gene, ASCC3L1 gene, BRD8 gene, C19orf43 gene, DDX55 gene, DKFZp564K142 gene, DPM3 gene, EEF2 gene, FAM73B gene, FLJ20303 gene, NCLN gene, C14orf173 gene, LRPPRC gene, and RCN1 gene.

### Claim 6 (depends on 5)

The anti-influenza virus agent according to claim 5,
wherein the gene is GBF1 gene.

### Claim 7 (depends on 5)

The anti-influenza virus agent according to claim 5,
wherein the anti-influenza virus agent is Golgicide A.

### Claim 8

A screening method for an anti-influenza virus agent which is a method of screening a candidate compound for an anti-influenza virus agent,
wherein a compound capable of suppressing or inhibiting expression of a gene that is at least one selected from the group including JAK1 gene, CHERP gene, DDX21 gene, DNAJC11 gene, EEF1A2 gene, HNRNPK gene, ITM2B gene, MRCL3 gene, MYH10 gene, NDUFS8 gene, PSMD13 gene, RPL26 gene, SDF2L1 gene, SDF4 gene, SFRS2B gene, SNRPC gene, SQSTM1 gene, TAF15 gene, TOMM40 gene, TRM2B gene, USP9X gene, BASP1 gene, THOC2 gene, PPP6C gene, TESC gene, PCDHB12 gene, CCDC56 gene, CLTC gene, CYC1 gene, NIBP gene, ZC3H15 gene, C14orf173 gene, ANP32B gene, BAG3 gene, BRD8 gene, CCDC135 gene, DDX55 gene, DPM3 gene, EEF2 gene, IGF2BP2 gene, KRT14 gene, S100A4 gene, GBF1 gene, ASCC3L1 gene, C19orf43 gene, DKFZp564K142 gene, FAM73B gene, FLJ20303 gene, NCLN gene, LRPPRC gene, and RCN1 gene or a function of a protein that the gene encodes is screened as the candidate compound for the anti-influenza virus agent.

### Claim 9 (depends on 8)

The screening method for an anti-influenza virus agent according to claim 8, comprising:
a process in which a target compound to be evaluated as a candidate compound for an anti-influenza virus agent is introduced into cells;
a process in which an expression level of the gene in the cells into which the compound is introduced is measured; and
a process in which, when the expression level of the gene is significantly lower than that of cells into which the compound is not yet introduced, the compound is selected as the candidate compound for the anti-influenza virus agent.

### Claim 10 (depends on 8)

The screening method for an anti-influenza virus agent according to claim 8,
wherein the protein that the gene encodes is an enzyme, and
wherein the screening method includes
a process in which enzyme activity of the protein that the gene encodes is measured under the presence of a target compound to be evaluated as a candidate compound for an anti-influenza virus agent; and
a process in which, when the enzyme activity of the protein in the presence of the compound is lower than that in the absence of the compound, the compound is selected as the candidate compound for the anti-influenza virus agent.
